# Anaconda Biomed SL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anaconda-biomed-sl

- Industry: Medical Devices & Equipment
- Headquarters: Barcelona, Spain
- Website: www.anaconda.bio
- Total disclosed funding: $17M
- Latest round: Series A (May 22, 2017)
- Investors on record: 4

## About

Anaconda Biomed SL develops advanced medical devices, focusing on innovative catheter systems for mechanical thrombectomies, addressing critical needs in stroke treatment with its specialized products. Founded in 2015 in Barcelona, Spain, Anaconda Biomed SL specializes in advanced catheter systems for thrombectomy procedures. In September 2026, Anaconda Biomed SL raised USD 56 million in venture funding led by Omega Funds, with participation from Sabadell Capital, Center for Technological & Industrial Development, Cofides, Asabys Partners and Ysios Capital Partners. The company was co-founded by Inyaki Galve and Ofir Arad, who possess relevant experience in the medical device industry. Anaconda Biomed S.L. specializes in innovative medical devices, primarily focusing on advanced catheter systems designed for performing mechanical thrombectomies. The company's flagship offerings, the ANA and ANA5 systems, consist of coaxial catheters that facilitate the safe and efficient removal of blood clots from neurovascular vessels. These devices have been engineered to support clot attachment to retrieval devices, thereby reducing the risks associated with clot detachment and increasing the efficacy of thrombectomy procedures. The products are intended for use in critical medical situations, specifically for patients experiencing acute ischemic strokes resulting from large vessel neurovascular occlusions. Anaconda Biomed serves healthcare professionals and hospitals across various markets, including Europe and North America, in need of reliable solutions for stroke treatment. Anaconda Biomed operates on a revenue model centered around the sale of its advanced catheter systems to hospitals and medical facilities, which utilize these devices for interventional procedures in acute ischemic stroke cases. The business transactions typically involve direct sales to healthcare providers, where the devices are offered as single-use, sterile products that are essential for thrombectomy interventions. Each of the company's products is positioned to address specific clinical needs, with pricing structured around the complexity and technology behind the devices. In 2017, the company reported no revenue, while for 2023, it recorded an EBITDA of EUR -1,262,028.40. Anaconda Biomed plans to leverage the recent EUR 20 million funding raised. The company will use the September 2026 funding to finalize the development of its product.

## Funding rounds

- Series A, May 22, 2017, $17M — Banco Sabadell, Innogest, Ysios Capital Partners, Omega Funds
- Seed, May 1, 2016 — Innogest

## Investors

- Innogest (https://capitalatlas.ai/funds/innogest) — Seed, Series A
- Banco Sabadell — Series A
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series A
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A